Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karie Runcie

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Oncologist|December 14, 2024
Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancerKarie Runcie, Yadriel Bracero, Avishai Samouha, et al.
JCO Oncology Practice|June 12, 2025
Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling InhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
JCO Oncology Practice|September 3, 2025
Erratum: Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling InhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
Cancer|November 2, 2025
Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
Cancer Cell|November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerJessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Cell Reports. Medicine|February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trialCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Oncologist|December 14, 2024
Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancerKarie Runcie, Yadriel Bracero, Avishai Samouha, et al.
JCO Oncology Practice|June 12, 2025
Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling InhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
JCO Oncology Practice|September 3, 2025
Erratum: Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling InhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
Cancer|November 2, 2025
Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
Cancer Cell|November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerJessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Cell Reports. Medicine|February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trialCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Pageof 2